Genzyme launches first tests for colon cancer risk:
This article was originally published in Clinica
Genzyme Genetics has launched two tests in the US designed to screen individuals at increased risk from two types of hereditary colon cancer. The first test detects mutations associated with hereditary nonpolyposis colon cancer (HNPCC), the most common form of hereditary colon cancer which affects between 4,000 and 8,000 people (or between 3% and 6% of all colorectal cancers) each year in the US. The second test is for a mutation associated with adenomatous polyposis coli, a type of colorectal cancer which is particularly prevalent in Ashkenazi Jews. The APCI1307K mutation that the test detects is found in almost 30% of Ashkenazi Jews with a personal and family history of this type of cancer. The new tests will only be available through specialised cancer centres for patients with a family history of these types of cancer.